CEO: With NDA under review, solid bank account, Yaupon's a catch
This article was originally published in Scrip
Executive Summary
With $14.4 million in new funding added to its coffers and a new drug application (NDA) under review at the US FDA for a patent-protected medicine that stands to be the first-of-its-kind on the US market for a rare disease – which could mean an additional seven years of data exclusivity protection – specialty pharma Yaupon Therapeutics has become an attractive potential partner or acquisition target for any drug maker to consider, said Chairman and CEO Steve Tullman.